Genmab PE Ratio 2019-2021 | GMAB

Current and historical p/e ratio for Genmab (GMAB) from 2019 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Genmab PE ratio as of October 22, 2021 is 75.37.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Genmab PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 46.73 75.37
2021-06-30 40.83 $0.62 65.85
2021-03-31 32.83 $1.30 25.25
2020-12-31 40.66 $1.09 37.30
2020-09-30 36.61 $1.29 28.38
2020-06-30 33.89 $2.42 14.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $30.695B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76